About Us

You’ve heard all about it but know almost nothing. That’s most of us.

Maybe your friend swears by it. Maybe you’ve tried it. Or just want to. For aches and pains. For worries and late nights. For your loved ones, your dog or your bum knee.

is your independent guide to hemp-derived cannabinoid wellness. Using laboratory testing, data algorithms and a world class Advisory Board of scientists and MDs, we lab test and analyze every product we sell. We tell you what you need to know, then make available the products that are exceptional.

Learn why only 20% of the products we test pass our stringent standards.

The TruDiligence Process

Third party laboratories conduct ultra high performance liquid chromatography (UHPLC) testing. Testing specifically for the psychoactive compound THC ensures compliance with the 2018 United States Farm Bill that all products contain less than 0.3% THC.


The TruPotency Science Team has developed a database of relevant cannabinoids, terpenes and other key ingredients and assigned a score for each product based on their contents. The TruPotency algorithm uses these scores to determine which products are right for you.

Science Team

Our Science Advisory Board -- PhDs and MDs, as well as our staff professionals have decades of experience in the cannabis industry that we use to vet all of our products.


Only a small percentage of the products we review pass our stringent standards.

TruPotency has assembled a diverse science advisory board of PhD scientists, doctors, and wellness professionals to push the boundaries of our scientific understanding. Our common thread is the study of cannabinoids and drug interactions within the body. From neuroscience, to cancer research, to dermatology, and plant microbiology, our collective goal is to use our knowledge to bring you the purest, most effective and safe cannabinoid products.

It’s not just about making sure a bottle has the labeled amount of cannabinoids. It’s also about testing for pesticides that could come from questionable growing practices, heavy metals from bad extraction techniques, and molds that can show up in organic material. No one has been willing to be a watchdog, so we are motivated to take on this task.

Adam Friedman, MD, FAAD

Adam Friedman


Adam Friedman, MD, FAAD is Professor and Interim Chair of Dermatology and serves as Residency Program Director, Director of Translational Research, and Director of the Supportive Oncodermatology Program in the Department of Dermatology at The George Washington University School of Medicine & Health Sciences. Dr. Friedman is currently investigating novel nanotechnologies that allow for controlled and sustained delivery of a wide spectrum of physiologically and medicinally relevant molecules, such as cannabinoids, with an emphasis on treating infectious diseases, accelerating wound healing, immune modulation, and correcting vascular dysfunction.

He holds multiple patents derived from these investigations, and has published over 170 papers/chapters and 2 textbooks on both his research as well as a variety of clinical areas in dermatology with an emphasis on emerging medical therapies. He has received multiple awards such as the American Dermatologic Association Young Leader Award, the American Society for Dermatologic Surgery Cutting Edge Research Award, the 2017 Elle Beauty Genius Award, and has been on the Washingtonian Top Doctors list since 2017.

Todd Vanderah, PhD

Todd Vanderah

PhD in Pharmacology

Dr. Vanderah is Head and Professor of Pharmacology, and is a Professor in the Departments of Neurology and Anesthesiology at The University of Arizona, College of Medicine, in Tucson. His research interests include mechanisms of cancer pain, neuronal integration in pain pathways, neurochemical release during conditions of neuropathy, neuronal plasticity, addiction, cannabinoid & opioid receptor pharmacology, as well as the discovery of novel targets for new medications.

His recent research details how select cannabinoids can act synergistically with opioids to inhibit chronic pain while blocking the opioid-induced rewarding behavior and decrease opioid-induced respiratory depression. Studies include investigation of selective cannabinoids in chronic administration and cognitive function. He is the Principle Investigator on multiple research grants, has authored over 170 original research articles, 3 Human Neuroscience books and 1 Pharmacology book. He has taught in the medical school for over 20 years and earned over 25 teaching awards.

Angela Kapp

Angela Kapp

Co-CEO, Co-Founder

A trailblazing corporate paradigm buster who digitized Estee Lauder and e-commed cosmetics. Moving from beauty to wellness is a natural progression for her and the customers she’s led for so long. Generationally refreshing and relatable.

Nate Lipton

Nate Lipton

Co-CEO, Co-Founder

A young entrepreneur. CannaCribs creator & host. Founder of GrowersHouse. Far from a weed-bro, Nate represents curiosity, thoroughness and high performance. Professional and accessible, he de-stigmatizes in what he does and how he does it.